Stock reports › US › Healthcare

Labcorp Holdings Inc. (LH) stock analysis

Labcorp hits record high after Q3 beat, trading near $373 with analysts raising targets

Labcorp (LH) closed at 372.92 on Nov 12, 2026, 0.22% below its 52-week and all-time high of 373.76, after an 11.17% earnings-day move on Oct 28. The stock is up 48.37% year to date and sits at 19.06× forward earnings, below the 19.53× sector median. Mean analyst target of 384.45 is only 3.09% above the price, and momentum indicators are stretched.

  • Price: 368.24
  • Market Cap (USD): $29.86B
  • P/E: 29.75×
  • Fwd P/E: 18.80×
  • Div Yield: 0.78%
  • 1Y Return: 37.97%
  • Mean Target: 384.45
  • Rating: Buy

Bull case

  • Q3 FY2026 EPS of 4.78 beat the 4.64 consensus by 3.02%, extending the beat streak to 13 quarters, and the stock rose 11.17% on Oct 28.
  • Revenue growth has been accelerating for 3 quarters, with Q3 FY2026 revenue of 3.81B versus 3.56B a year earlier, and operating margin is up 1.43% over the year to 11.12%.
  • Forward P/E of 19.06× is 29.16% below the industry median of 26.85×, while free cash flow of 1.29B gives a 4.26% FCF yield, at the 68th percentile of US Healthcare.

Bear case

  • The price is 27.98% above the 200-day average, RSI14 is 71.66 and Stochastic K is 96.77, so the shares look stretched after an 18.68% one-month gain.
  • Net debt is 6.51B, or 3.02× EBITDA, and goodwill of 7.18B is large relative to 8.85B of equity; debt-to-equity of 0.77× is at the 69th percentile of the sector.
  • Mean target of 384.45 implies just 3.09% upside, 9 of 35 analyst ratings are Hold, and insiders made 3 sales and no buys in the last 90 days (net -1.5M).

What to watch

  • Ex-dividend date on Nov 24, 2026 for the 0.72 quarterly dividend, payable Dec 11, 2026.
  • The 52-week and all-time high of 373.76 and the 10-day average of 365.17 as near-term support and resistance.
  • Next earnings date is not on file; the last report was Oct 28, 2026, so timing may differ from screen assumptions.
  • Short interest, last reported at 3.14% of float on Oct 30, 2026, and any change in analyst ratings after the recent target raises.

General

Labcorp provides diagnostic laboratory services to medical professionals, healthcare facilities, pharmaceutical firms, researchers and patients. The business is growing steadily and the stock has re-rated sharply, now sitting at a record high. Valuation is near sector medians while analysts are broadly positive.

Business and trading

Labcorp Holdings began operations on April 16, 2024, is based in Burlington, NC and has 71,000 employees. Trailing revenue is 14.59B with net income of 1.00B and EPS of 12.19. Revenue grew 6.02% year over year, and the stock returned 42.55% over one year.

Valuation in context

Forward P/E is 19.06× versus the sector median of 19.53× (46th percentile) and the industry median of 26.85×. Trailing P/E of 30.12× equals the sector median. The PEG of 2.84× reflects expected EPS growth of 6.70% next year, at the 23rd percentile of the sector.

Analysts and market signals

Consensus rating is Buy (26 Buy, 9 Hold, 0 Sell as of Nov 12, 2026), with a mean target of 384.45 from analysts. After earnings, Leerink, Barclays, UBS, Morgan Stanley, Baird and Deutsche Bank raised targets, and HSBC posted 410 on Nov 5. A Seeking Alpha piece on Oct 29 warned optimism may be overdone.

Long-term investor

Labcorp has rebuilt earnings after a weak 2023, with fiscal 2025 EPS of 10.46 against 4.77 in 2023, but remains below the 24.38 of 2021. Returns are around sector medians and the balance sheet carries meaningful debt. Valuation is moderate, though growth is below peers.

Growth durability

Revenue 3-year CAGR is 5.55% while the 5-year figure is -0.04%, reflecting the post-2021 decline from 13.14B to 11.86B in 2022 and recovery to 13.95B in 2025. EPS 3-year CAGR is -9.17%. Four quarters of rising revenue from 3.52B (Q4 FY2025) to 3.81B (Q3 FY2026) show a better trend.

Margins and returns

Operating margin of 11.12% (49th percentile) and ROIC of 8.35% versus the 8.66% sector median are average. ROE is 11.45%. Gross margin of 27.95% is low versus the 63.53% sector median, but operating margin improved 1.43% over the year.

Balance sheet and capital return

Total debt is 6.78B against 261.8M of cash; interest coverage is 7.05× and the Piotroski score is 7. Shares outstanding fell 2.51% in a year; fiscal 2025 buybacks were 450.0M and dividends 240.7M. The 0.77% yield has a 23.63% payout ratio and 15.78% three-year growth.

Ownership and revisions

Institutions hold 97.18%, up 2.16% over three months. Next-year consensus EPS is 19.74 and the 30-day EPS revision is 0.79%. Insiders sold in August and November 2026, including the CEO on Aug 11 (1.5M); there were no insider buys.

Swing trader

LH is in a strong uptrend, trading above all key averages at a record high, with a relative strength rating of 93. Momentum is extended and the stock has pulled back little, so risk is of a short-term pause near 373.76.

Trend and momentum

Price of 372.92 is above the 20-day (347.03), 50-day (328.04) and 200-day (291.38) averages. The golden cross occurred Jul 23, 2026. ADX14 is 37.47, signaling a strong trend. RSI14 is 71.66, RSI2 is 80.63 and MACD of 13.87 is above its signal of 11.78.

Recent sessions and levels

The stock jumped from 331.17 on Oct 27 to 360.25 on Oct 28 on 1.8M shares. It has held between 353.92 and 372.23 closes since, and Nov 12 volume is light at 0.55× relative. The 20-day high is 373.76 and low 314.69; the upper Bollinger Band is 387.64.

Risk and flow

ATR14 is 10.19, or 2.74% of price; 30-day realized volatility is 31.40%. Short interest is 3.14% of float, with 3.01 days to cover as of Oct 30. No upgrades or downgrades in 30 days; Oct 29 actions were reiterations. Ex-dividend Nov 24.

Options

Implied volatility is low relative to its own history and below realized volatility, so option premium is cheap by that measure. Term structure is flat and call open interest dominates. Liquidity is thin.

Volatility level

IV30 is 24.34% with an IV rank of 14 and IV percentile of 31, against a 52-week range of 18.97% to 56.83%. IV30 fell 4.3 points over 20 days. Term structure is flat (IV60 23.13%, IV90 24.51%) and 25-delta skew is +4.1 points.

Implied versus realized

IV30 trails 30-day realized volatility of 31.40%: the IV/HV ratio is 0.78× and the volatility risk premium is -13.0 points. Option premium is therefore not rich relative to recent movement. The expected 30-day move is 25.97, or 6.98%, and the 7-day move is 3.37%.

Earnings and premium yields

The Oct 28 move was 11.17% versus an implied 13.94%; the 8-quarter average is 4.49% and median 3.23%. Average IV crush is 21.37%. For the Dec 18 expiry (37 days), the 30-delta put at 360.00 yields 18.29% annualized and the 30-delta call at 390.00 yields 13.59%.

Liquidity and activity

Options volume is 1.2K, 0.76× the 20-day average, with open interest of 8.7K and a liquidity score of 49. ATM open interest is only 6 contracts and there are no weekly options. Put/call volume is 1.01× and open interest ratio is 0.51×, with 1.3M of net call premium.

Analysis written November 12, 2026 from Qanvo data as of November 12, 2026. AI-generated, for information only; not investment advice.